Market Opportunity Assessment Study: Netupitant - Palonosetron FDC is Expected to Reach USD 515.0 Million in 2018: Transparency Market Research

Informations

• Publié par: transparency-market-research
• Nombre de lectures: 10
• Langue: English

Extrait

Market Opportunity Assessment Study: Netupitant - Palonosetron FDC is Expected to Reach USD 515.0 Million in 2018: Transparency Market Research

PR Newswire ALBANY, New York, October 24, 2012

ALBANY, New York,October 24, 2012/PRNewswire/ --

According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Netupitant - Palonosetron FDC - Global Market Opportunity Assessment Study, 2012-2018", the global Netupitant - Palonosetron FDC sales are expected to reachUSD 515.0 millionby 2018. The global Chemotherapy-induced nausea and vomiting (CINV) market is estimated to reach USD 1.7 billionby 2015 at a growth rate of 7.1%, whereas country such asSouth Africa is estimated to constitute 9% of the CINV market by 2015, due to prevalent cancer related conditions and subsequent increase in C INV patient pool. Asian region is expected to witness largest patient share for CINV contributing majorly to the total CINV patient pool. Hence, Asian market is expected to have huge growth potential for Netupitant - Palonosetron FDC.

Browse the full report athttp://www.transparencymarketresearch.com/netupitan t-palonosetron-fdc- market.html

Chemotherapy is one of the treatment options utilized by oncologists in treating different types of cancers. Nausea and vomiting are the most common side-effects experienced by cancer patients when administered with chemotherapy. Netupitant-palonosetron, which is currently in Phase III trials helps in preventing CINV. The blockage of P/NK1 receptors by Netupitant in the central nervous system inhibits the binding of endogenous tachykinin neuropeptide substance and this result in preventing the chemotherapy-induced nausea and vomiting. Moreover, Palonosetron helps in the blockage of serotonin at 5-hydroxytryptamine type 3 (5-HT3) receptors and it also helps in the chemotherapy-induced nausea and vomiting.

Netupitant-Palonosetron FDC is estimated to answer significant unmet needs of the CINV market post its launch that is expected to be commercialized in 2014, as it would overcome the problems associated with current treatment with 5-HT3 receptor antagonists. Similar to Emend, Netupitant-Palonosetron FDC would gain considerable patient pool after its estimated launch in 2014, and subsequently match the patient share of Aloxi by 2018. Netupitant- Palonosetron FDC sales are expected to reach an estimatedUSD 515.0 million USDby 2018. FDC combination of 5-HT3 receptor antagonist and neurokinin-1 (NK1) receptor antagonist have shown better efficacy results in Phase II clinical trials for CINV patients and would thus lead to high uptake due to shifting physician and patient preference pattern towards better treatment for CINV.

Related & Recently Published Reports by Transparency Market Research

Global Cardiovascular Devices Market

Global Stents Market

Global Ultrasound Market

Magnetic Resonance Imaging (MRI) Market

XRay Market

Computed Tomography Industry

Global Catheters Industry

Enteral Feeding Market

Endoscopy Devices Market

Ophthalmology Devices Industry

Laparoscopic Devices Market

Global Infertility Market

RFID In Healthcare

In Vitro Toxicity Testing

The lack of approval to any other antagonist for the prevention of delayed-onset CINV in patients getting highly emetogenic chemotherapy, Palonosetron is expected to witness higher growth. It is expected to grow at a higher rate during the forecasted period in both developed and developing regions such as South Africa and Asia among others.

CINV can cause cancer patients to withdraw from therapy due to increased medical costs, often leading to higher mortality and higher medical spending. So, patients and providers would realize the benefits of finding alternative CINV therapies, such as Netupitant-Palonosetron FDC .

New entrants to this market have historically benefited from rapid uptake, driven both by clinical advantages and by favorable reimbursement dynamics, from which Netupitant-Palonosetron FDC is poised to benefit upon approval.

There is certain advantage of the Netupitant - Palonosetron as it would be the only FDC approved for treating chemotherapy induced nausea and vomiting that is likely to drive this market in the near future. Moreover, it is effective in the body for longer period of time and will help in achieving better patient compliance. However, lack in the number of clinical trials is likely to slower the growth of this market but the rising cancer population is likely to further create an opportunity in this market.

Browse allMedical Devices Market ResearchReports

Upcoming Reports inMedical Devices Market

Anti Microbial Coating Market

Breast Pumps Market

Gynecological Devices Market

Radiotherapy Devices Market

Blood Pressure Monitoring & Measurement Instruments Market

Sleep Apnea Devices Market

Medical Robotics Market

Dental Prosthetics Market

Dental Consumables Market

Pulse Oximeters Market

About Us

Transparency Market Research is a global market intelligence company, providing global business inform ation reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Sheela AK 90 Sate Street, Suite 700 Albany, NY 12207 Tel: [phone] USA - Canada Toll Free: 866-552-3453 Email:[e-mail] Search Reports:http://www.mrrse.com/